12 months from date of receipt / reconstitution, 2 to 8 °C as supplied
| 应用 | 稀释度 |
|---|---|
| ELISA | 1.221-5000 ng/ml |
Bevacizumab works by blocking a protein called VEGF, which some cancer cells produce in large amounts. Blocking VEGF may prevent the growth of new blood vessels that tumors need to grow. Bevacizumab is a type of targeted therapy called an angiogenesis inhibitor. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).
Immobilized human VEGF at 0.5 μg/ml (50μL/well) can bind to Bevacizumab with a linear range of 1.221 ng/ml to 5 μg/ml.
您现在的位置：
